Slide 1: Immunic Therapeutics First Quarter 2024 Financial Results and Corporate Update
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities
Slide 3: Agenda
Agenda First Quarter 2024 Financial Results and Corporate Update 02 | First Quarter 2024 and Subsequent Highlights 04 | Q&A Session Financial and Operating Results Summary and Highlights 03 | Clinical Development Programs 3 | © immunic, inc. | May/08/2024 & Immunic
Slide 4: First Quarter 2024 and Subsequent Highlights
Slide 5: January: Three-Tranche Private Placement of up to $240M, Cash Runway Extended Into Q3/2025
January: Three-Tranche Private Placement of up to $240M, Cash Runway Extended Into Q3/2025 Based on Initial S8OM Tranche Private Investmentin Public Equity (“PIPE”) financing Total Gross Proceeds Participating Investors Closing Date Lead Placement Agent / Placement Agent / Capital Markets Advisors 5
Slide 6: February: Presented Data From Phase CALLIPER and CALVID-1 Trials at ACTRIMS Forum 2024
February: Presented Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (February 29-March 2 in West Palm Beach, FL) CALVID-1: Potential Contribution to the Reduction of Fatigue in MS Patients CALLIPER Interim Analysis: Clear Separation in NfL Levels Acro
Slide 7: March: Data Presentations at Frontiers in Medicinal Chemistry and Society for Virology Meeting
March: Data Presentations at Frontiers in Medicinal Chemistry and 33rd Annual Meeting of the Society for Virology Vidofludimus Calcium Potently Activates Neuroprotective Transcription Factor Nurr1 Potent Broad-Spectrum Antiviral Activity In Vitro = March 17-20 in Munich, Germany = March 25-28 in Vie
Slide 8: March: Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in MS
March: Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in MS Notice of Allowance from the USPTO for patent application 16/981,122, covering the composition- of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material Claims are exp
Slide 9: April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco
9 | © immunic, inc. | May/08/2024 April: Hosted In-Person Multiple Sclerosis R&D Day in San Francisco =) Could Vidofludimus Calcium be the First Neuroprotective 525) Treatment Option for Multiple Sclerosis? Immunic speakers: = Daniel Vitt, PhD, CEO & President = Hella Kohlhof, PhD, CSO = Andreas Mue
Slide 10: Financial and Operating Results
Slide 11: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $18,736] $22,963] General and administrative 5,145 4,288] Total operating expenses 23,881 27,251 Loss from
Slide 12: Clinical Development Programs
Slide 13: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 Top-line data from phase 2 CALLIPER trial in PMS expected in April 2025 Interim, non-binding futility analysis of phase 3 IMU-838 ENSURE program expected in late 2024 in RMS Readout of first phase 3 ENSURE trial anticipated in Q2/2026, second in
Slide 14: Q&A Session
Slide 15: Summary and Highlights
Slide 16: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Vidofludimus Calcium (umu-838) Ulcerative Colitis (UC) — CALDOSE-1 Tri IMU-856 IMU-381 = Completed or ongoing In preparation or planned 16 | © immunic, inc. |
Slide 17: Thank You!
Thank You! Jessica Breu Vice President Investor Relations & Communications & Phone: +49-89-2080477-09 ©& Email: ir@imux.com © Web: www.imux.com 17 | © immunic, inc. | May/08/2024 Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grifelfing (Mu